Global Venlafaxine Market, By Drug Class (Antidepressant, Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)), Application (Panic Disorder, Depression, Anxiety, Social Anxiety Disorder, Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Extended Release Capsule, Extended Release Tablet, Others), Route of Administration (Oral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Venlafaxine Market
Venlafaxine market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4% in the above mentioned forecast period.
Venlafaxine is an antidepressant that is also used to treat panic attacks, anxiety, and social anxiety disorder (also called social phobia). It has the potential to boost your mood and energy level, as well as rekindle your enthusiasm in daily activities. It may also help to reduce anxiety, fear, panic attacks. Venlafaxine is a reuptake inhibitor of serotonin and norepinephrine (SNRI). It works by assisting in the restoration of the brain's natural chemical equilibrium. This medication is available under brand names including effexor and effexor XR.
The rise in the prevalence of anxiety and social anxiety disorder will act a major driver for the expansion of venlafaxine market. Furthermore, increasing geriatric population, rising healthcare expenditure and increase in the number of patients suffering from depression are the factors that will expand the venlafaxine market. Other factors including rise in the growing government initiatives, changing lifestyle and rising awareness will positively impact the market growth rate.
Moreover, the rise in the research and development activities and strategic collaborations will provide beneficial opportunities for the venlafaxine market in the forecast period of 2021-2028.
However, high cost of drug and side effects associated with venlafaxine such as loss of appetite, diarrhea, headache, nausea, dizziness, seizure and others. All these factors hamper the market growth. Lack of awareness will further challenge the venlafaxine market in the forecast period mentioned above.
This venlafaxine market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the venlafaxine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Venlafaxine Market Scope and Market Size
The venlafaxine market is segmented on the basis of drug class, application, demographic, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of drug class, the venlafaxine market is segmented into antidepressant, selective serotonin and norepinephrine reuptake inhibitors (SNRIs).
- On the basis of application, the venlafaxine market is segmented into panic disorder, depression, anxiety, social anxiety disorder and others.
- On the basis of demographic, the venlafaxine market is segmented into adult, pediatric and geriatric.
- On the basis of dosage form, the venlafaxine market is segmented into tablet, extended release capsule, extended release tablet and others. Tablet segment is further sub-segmented into 25mg, 37.5mg, 50mg, 75mg, and 100mg. Extended release capsule segment is further sub-segmented into 37.5mg, 75mg and 150mg. Extended release tablet segment is further sub-segmented into 37.5mg, 75mg, 150mg and 225mg.
- On the basis of route of administration, the venlafaxine market is segmented into oral and others.
- On the basis of end-users, the venlafaxine market is segmented into clinic, hospital and others.
The venlafaxine market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Venlafaxine Market Country Level Analysis
Venlafaxine market is analyzed and market size information is provided by the country, drug class, application, demographic, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the venlafaxine market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the venlafaxine market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities and growing government support in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Venlafaxine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Venlafaxine Market Share Analysis
Venlafaxine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to venlafaxine market research.
Some of the major players operating in the venlafaxine market are Amgen Inc., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, AstraZeneca, Johnson & Johnson Private Limited, Abbott, Eisai Co., Ltd., Merck & Co., Inc., Genentech, Inc., Otsuka America Pharmaceutical, Inc., Kanghong Pharmaceutical, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited., Sanofi, and Sun Pharmaceutical Industries Ltd., among others.
SKU-